🚀 VC round data is live in beta, check it out!
Alnylam Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Alnylam Pharmaceuticals and similar public comparables like Sun Pharma, Sandoz, BeOne Medicines, Teva Pharmaceuticals and more.
Alnylam Pharmaceuticals Overview
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway in cells that enables sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Founded
2003
HQ
Employees
2.5K
Website
Sectors
Financials (LTM)
EV
$40B
Alnylam Pharmaceuticals Financials
Alnylam Pharmaceuticals reported last 12-month revenue of $4B and EBITDA of $843M.
In the same LTM period, Alnylam Pharmaceuticals generated $3B in gross profit, $843M in EBITDA, and $499M in net income.
Revenue (LTM)
Alnylam Pharmaceuticals P&L
In the most recent fiscal year, Alnylam Pharmaceuticals reported revenue of $4B and EBITDA of $673M.
Alnylam Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $4B | XXX | $4B | XXX | XXX | XXX |
| Gross Profit | $3B | XXX | $3B | XXX | XXX | XXX |
| Gross Margin | 79% | XXX | 82% | XXX | XXX | XXX |
| EBITDA | $843M | XXX | $673M | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 18% | XXX | XXX | XXX |
| EBIT Margin | 16% | XXX | 14% | XXX | XXX | XXX |
| Net Profit | $499M | XXX | $314M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 8% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Alnylam Pharmaceuticals Stock Performance
Alnylam Pharmaceuticals has current market cap of $41B, and enterprise value of $40B.
Market Cap Evolution
Alnylam Pharmaceuticals' stock price is $309.66.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $40B | $41B | -3.3% | XXX | XXX | XXX | $2.35 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAlnylam Pharmaceuticals Valuation Multiples
Alnylam Pharmaceuticals trades at 9.3x EV/Revenue multiple, and 47.1x EV/EBITDA.
EV / Revenue (LTM)
Alnylam Pharmaceuticals Financial Valuation Multiples
As of April 18, 2026, Alnylam Pharmaceuticals has market cap of $41B and EV of $40B.
Equity research analysts estimate Alnylam Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Alnylam Pharmaceuticals has a P/E ratio of 82.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $41B | XXX | $41B | XXX | XXX | XXX |
| EV (current) | $40B | XXX | $40B | XXX | XXX | XXX |
| EV/Revenue | 9.3x | XXX | 10.7x | XXX | XXX | XXX |
| EV/EBITDA | 47.1x | XXX | 58.9x | XXX | XXX | XXX |
| EV/EBIT | 58.8x | XXX | 79.1x | XXX | XXX | XXX |
| EV/Gross Profit | 11.7x | XXX | 13.1x | XXX | XXX | XXX |
| P/E | 82.8x | XXX | 131.7x | XXX | XXX | XXX |
| EV/FCF | 46.8x | XXX | 66.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Alnylam Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Alnylam Pharmaceuticals Margins & Growth Rates
Alnylam Pharmaceuticals' revenue in the last 12 month grew by 43%.
Alnylam Pharmaceuticals' revenue per employee in the last FY averaged $1.5M, while opex per employee averaged $1.0M for the same period.
Alnylam Pharmaceuticals' rule of 40 is 72% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Alnylam Pharmaceuticals' rule of X is 146% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Alnylam Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 43% | XXX | 50% | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Growth | 69% | XXX | 85% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 72% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 146% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.5M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 30% | XXX | 33% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 34% | XXX | 36% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 68% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Alnylam Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Alnylam Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Sun Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Sandoz | XXX | XXX | XXX | XXX | XXX | XXX |
| BeOne Medicines | XXX | XXX | XXX | XXX | XXX | XXX |
| Teva Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Bayer | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alnylam Pharmaceuticals M&A Activity
Alnylam Pharmaceuticals acquired XXX companies to date.
Last acquisition by Alnylam Pharmaceuticals was on XXXXXXXX, XXXXX. Alnylam Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Alnylam Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAlnylam Pharmaceuticals Investment Activity
Alnylam Pharmaceuticals invested in XXX companies to date.
Alnylam Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Alnylam Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Alnylam Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Alnylam Pharmaceuticals
| When was Alnylam Pharmaceuticals founded? | Alnylam Pharmaceuticals was founded in 2003. |
| Where is Alnylam Pharmaceuticals headquartered? | Alnylam Pharmaceuticals is headquartered in United States. |
| How many employees does Alnylam Pharmaceuticals have? | As of today, Alnylam Pharmaceuticals has over 2K employees. |
| Who is the CEO of Alnylam Pharmaceuticals? | Alnylam Pharmaceuticals' CEO is Yvonne L Greenstreet. |
| Is Alnylam Pharmaceuticals publicly listed? | Yes, Alnylam Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of Alnylam Pharmaceuticals? | Alnylam Pharmaceuticals trades under ALNY ticker. |
| When did Alnylam Pharmaceuticals go public? | Alnylam Pharmaceuticals went public in 2004. |
| Who are competitors of Alnylam Pharmaceuticals? | Alnylam Pharmaceuticals main competitors are Sun Pharma, Sandoz, BeOne Medicines, Teva Pharmaceuticals. |
| What is the current market cap of Alnylam Pharmaceuticals? | Alnylam Pharmaceuticals' current market cap is $41B. |
| What is the current revenue of Alnylam Pharmaceuticals? | Alnylam Pharmaceuticals' last 12 months revenue is $4B. |
| What is the current revenue growth of Alnylam Pharmaceuticals? | Alnylam Pharmaceuticals revenue growth (NTM/LTM) is 43%. |
| What is the current EV/Revenue multiple of Alnylam Pharmaceuticals? | Current revenue multiple of Alnylam Pharmaceuticals is 9.3x. |
| Is Alnylam Pharmaceuticals profitable? | Yes, Alnylam Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Alnylam Pharmaceuticals? | Alnylam Pharmaceuticals' last 12 months EBITDA is $843M. |
| What is Alnylam Pharmaceuticals' EBITDA margin? | Alnylam Pharmaceuticals' last 12 months EBITDA margin is 20%. |
| What is the current EV/EBITDA multiple of Alnylam Pharmaceuticals? | Current EBITDA multiple of Alnylam Pharmaceuticals is 47.1x. |
| What is the current FCF of Alnylam Pharmaceuticals? | Alnylam Pharmaceuticals' last 12 months FCF is $848M. |
| What is Alnylam Pharmaceuticals' FCF margin? | Alnylam Pharmaceuticals' last 12 months FCF margin is 20%. |
| What is the current EV/FCF multiple of Alnylam Pharmaceuticals? | Current FCF multiple of Alnylam Pharmaceuticals is 46.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.